Literature DB >> 22169802

Stem cells: Transplants on trial.

Elie Dolgin.   

Abstract

Mesh：

Year:  2011        PMID： 22169802     DOI： 10.1038/480S46a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

1.  Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Authors:  Bart Barlogie; Robert A Kyle; Kenneth C Anderson; Philip R Greipp; Hillard M Lazarus; David D Hurd; Jason McCoy; Dennis F Moore; Shaker R Dakhil; Keith S Lanier; Robert A Chapman; Jeana N Cromer; Sydney E Salmon; Brian Durie; John C Crowley
Journal:  J Clin Oncol       Date:  2006-01-23       Impact factor: 44.544

2.  High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.

Authors:  J P Fermand; P Ravaud; S Chevret; M Divine; V Leblond; C Belanger; M Macro; E Pertuiset; F Dreyfus; X Mariette; C Boccacio; J C Brouet
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

3.  Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

Authors:  Bo Björkstrand; Simona Iacobelli; Ute Hegenbart; Astrid Gruber; Hildegard Greinix; Liisa Volin; Franco Narni; Pellegrino Musto; Meral Beksac; Alberto Bosi; Giuseppe Milone; Paolo Corradini; Hartmut Goldschmidt; Theo de Witte; Curly Morris; Dietger Niederwieser; Gösta Gahrton
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

4.  Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

Authors:  Bart Barlogie; Guido J Tricot; Frits van Rhee; Edguardo Angtuaco; Ron Walker; Joshua Epstein; John D Shaughnessy; Sundar Jagannath; Vanessa Bolejack; Jennifer Gurley; Antje Hoering; David Vesole; Raman Desikan; David Siegel; Jayesh Mehta; Seema Singhal; Nikhil C Munshi; Madhav Dhodapkar; Bonnie Jenkins; Michel Attal; Jean-Luc Harousseau; John Crowley
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

5.  Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

Authors:  Amrita Krishnan; Marcelo C Pasquini; Brent Logan; Edward A Stadtmauer; David H Vesole; Edwin Alyea; Joseph H Antin; Raymond Comenzo; Stacey Goodman; Parameswaran Hari; Ginna Laport; Muzaffar H Qazilbash; Scott Rowley; Firoozeh Sahebi; George Somlo; Dan T Vogl; Daniel Weisdorf; Marian Ewell; Juan Wu; Nancy L Geller; Mary M Horowitz; Sergio Giralt; David G Maloney
Journal:  Lancet Oncol       Date:  2011-09-29       Impact factor: 41.316

6.  Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Authors:  Bijay Nair; Frits van Rhee; John D Shaughnessy; Elias Anaissie; Jackie Szymonifka; Antje Hoering; Yazan Alsayed; Sarah Waheed; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.